Abstract. ARHI is a Ras-related imprinted tumor-suppressor gene that inhibits cancer cell growth and motility. ARHI is downregulated in the majority of ovarian cancer cells, and promoter methylation is considered to be associated with its loss of expression. However, the underlying mechanisms are not well understood. Thus, the present study aimed to investigate the specific functions of ARHI and its methylation in ovarian cancer cell proliferation. Furthermore, we examined the possible role of acetylated STAT3 in modulating the expression of ARHI and its methylation. In accordance with the majority of previous studies, reduced ARHI expression was found in epithelial ovarian cancer tissues and cancer cell lines as indicated by immunohistochemistry and RT-PCR. In addition, CpG islands Ⅰ and Ⅱ within ARHI promoter regions were partially methylated or hypermethylated in cancer cell lines (SKOV-3 and HO-8910) as analyzed by pyrosequencing assays, resulting in enhanced proliferation of the cancer cells. This proliferation was reversed by the administration of 5-aza-2'-deoxycytidine. Subsequently, we demonstrated that STAT3 acetylation was increased in HO-8910 cells, and the methylation status of CpG Ⅰ was altered in response to the acetylation of STAT3 using western blotting. Finally, chromatin immunoprecipitation (ChIP) and IP analysis indicated that acetylated STAT3 bound to the ARHI promoter and recruited DNA methyltransferase 1 for genetic modification. In conclusion, acetylated STAT3-induced promoter gene methylation accounts for the loss of ARHI expression and cancer cell proliferation.
Introduction
ARHI, first described in 1999 by Yu et al using differential display PCR (1) , is a maternally imprinted tumor-suppressor gene located on chromosome 1p31 that encodes a 26-kDa small GTP-binding protein sharing 54-62% amino acid homology with Ras and Rap (2, 3) . Rather than acting as a proto-oncogene similar to ras and rap, ARHI is responsible for inducing apoptosis and inhibiting cancer cell growth and motility (4, 5) . It has been reported that ARHI is expressed consistently in primary ovarian and breast epithelial cells but is dramatically downregulated in the majority of ovarian, breast, and even pancreatic and hepatocellular cancer cells (6) . Subsequently, loss of heterozygosity (LOH) of ARHI was found in ~40% of ovarian cancer cells. Multiple factors appear to contribute to the abnormal gene conversion (2) . Although the definite molecular pathogenesis of LOH has not been elucidated, oxidative stress is suggested to be associated with the LOH-mediated carcinogenesis of ovarian cancer (7) . On the other hand, promoter methylation-induced ARHI silencing is also critical to downregulated expression of ARHI.
Three potential CpG islands in the ARHI gene of ~300 bp each have been identified by genomic structure analysis. Two of them (CpG islands I and II) are located within the promoter and adjacent exon 1 of the ARHI gene, while CpG island III is located in the protein-encoding region of exon 2 (8) . Accumulating evidence indicates that the promoter methylation status is closely related to reduced ARHI expression and malignant proliferation of ovarian cancer. Feng et al (9) reported that ARHI CpG islands I and II are hypermethylated in 31 and 12% of ovarian cancers, respectively. However, how ARHI is methylated and regulated requires further investigation.
STAT3, signal transducer and activator of transcription 3, a well-known transcription activator for many genes, has been reported to inhibit gene expression. The importance of phosphorylation in regulating STAT3 functions has been the STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer subject of intense scrutiny; at the same time, acetylation of STAT3 in mediating cancer progression is gradually surfacing and has attracted increased attention (10) (11) (12) . STAT3 has been shown to increase methylation of CpG islands in certain tumorsuppressor genes through regulation of the expression and interaction with DNA methyltransferase 1 (DNMT1), which plays key roles in maintenance of the methylation status as well as inhibition of tumor-suppressor genes through aberrant CpG island methylation. Thus, dysregulation of STAT3 could relate, in part, to loss of function of critical tumor-suppressor genes, which may exaggerate the malignant proliferation and invasiveness of ovarian cancer cells. To date, ovarian cancer still ranks third in incidence and first in mortality among all gynecological malignancies worldwide, of which epithelial ovarian cancer (EOC), including endometrioid adenocarcinoma (EAC), clear cell carcinoma (CCC) and other types, is the leading cause of cancer-related death in women, with a 5-year survival rate less than 20% (13, 14) . Therefore, understanding the underlying mechanisms of cellular carcinogenesis and apoptosis regulation are of paramount importance. Our study was carried out to investigate the specific functions of ARHI and its methylation in ovarian cancer cell proliferation. Furthermore, we examined the possible role of acetylated STAT3 in modulating the expression of ARHI and its methylation, which may be an important therapeutic strategy for treating ovarian cancer.
Materials and methods
Cell lines, tissue samples and regents. The human ovarian cancer cell lines (SKOV3 and HO-8910) were obtained from the American Type Cell Culture Collection (ATCC, Manassas, VA, USA), and early passages of normal human ovarian epithelial cell lines (NOE095 and HOSEpiC) were purchased from ScienCell Research Laboratories (San Diego, CA, USA) and deemed free of mycoplasma and bacterial contaminants. The SKOV3 and HO-8910 cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated FBS at 37˚C with 5% CO 2 , while the NOE095 and HOSEpiC cells were cultivated in Ovarian Epithelial Cell Medium (OEpiCM) obtained from ScienCell Research Laboratories under the same conditions. Furthermore, an HO-8910 cell line harboring the endogenous STAT3 K685R mutation was established as previously described (15) using a homologous recombinationmediated knock-in strategy.
Twenty pairs of matched ovarian cancers and normal tissues from the same patients (mean age 38±7 years) were obtained from the Department of Gynecology and Obstetrics, at General Hospital of PLA, between January 2011 and April 2011. All tissues and brushings were fresh-frozen and stored at -80˚C. The present study was approved and monitored by the Ethics Committee of the General Hospital of PLA.
5-Aza-2'-deoxycytidine (5-Aza), resveratrol and trichostatin were purchased from Sigma-Aldrich, and administered to the cell cultures at 0.5-1 µM, 500 ng/ml and 10 µM, respectively.
Immunohistochemical staining. Paraffin-embedded normal ovarian epithelium tissues and ovarian cancer tissues were sectioned and mounted on polylysine-coated slides, dewaxed in xylene and rehydrated using a graded ethanol series, before being washed three times with phosphate-buffered saline (PBS). After initial deparaffinization, endogenous peroxidase activity was blocked using 0.3% hydrogen peroxide, and the sections were steamed in 1X Diva Decloaker (Biocare Medical, Concord, CA, USA) for 1 h to restore latent epitopes. The slides were then incubated with an anti-ARHI antibody (C-12) obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) at a final concentration of 15 µg/ml for 3 h at 37˚C. Thorough washing in 0.01 mol/l PBS was then performed. The slides were incubated for 30 min with each biotin-labeled secondary antibody, and then with streptavidin/peroxidase. Subsequently, after administration of diaminobenzidine substrate, the tissue sections were lightly counterstained with hematoxylin for ~40 sec and then fixed with neutral balata for observation.
Real-time RT-PCR.
RT-PCR was performed to investigate the expression of ARHI. Total RNA of all normal ovarian epithelial cells (NOE095 and HOSEpiC) and cancer cells (SKOV3 and HO-8910) as well as normal and cancerous tissues were extracted and purified using an RNeasy Mini kit according to the manufacturer's instructions (Qiagen, Santa Clarita, CA, USA). After assessing RNA purity, 5 µg of RNA was used as the template for PCR. ARHI primers (sense 5'-TCTGCCC GCCCTGCTTAT-3' and antisense 5'-TTGCCGTCGCCACTC TTG-3') were used with GAPDH primers (sense 5'-GCCAAA AGGGTCATCATCTC-3' and antisense 5'-GTAGAGGCAG GGATGATGTTC-3') as the internal control. Amplification cycles consisted of 94˚C for 3 min, then 33 cycles at 94˚C for 1 min, 58˚C for 1 min, and 72˚C for 1.5 min, followed by 72˚C for 15 min. Aliquots of the PCR products were electrophoresed on 1.5% agarose gels, and PCR fragments were visualized by ethidium bromide staining.
Methylation analysis of the A R HI CpG islands.
Pyro-sequencing analysis performed as previously described (16) was used to measure the ARHI promoter CpG Ⅰ and Ⅱ methylation status in all cell lines. Briefly, genomic DNA was extracted from the cell lines using the QIAamp DNA Mini kit (Qiagen) and treated with bisulfite to convert all the unmethylated cytosines to uracils while conserving all the methylated cytosines. After treatment, 1-µl aliquots were amplified by PCR. The pyrosequencing primers were as follows: CpGⅠ-F, 5'-GTAAGGGAGAAAGAAGTTAGA-3' and CpGⅠ-R (50-Biotin), 5'-biotin-TA CTATCCTAACAAAA CCCTC-3'; CpGⅡ-F, 5'-GTTGGGTTAGTTTTTTATAGTT GGTT-3' and CpGⅡ-R (50-Biotin), 5'-biotin-AACCAAAC AACCTAAAAAACAAATAC-3'.
The biotinylated PCR products were purified and subjected to pyrosequencing using the PSQHS 96A Pyrosequencing System and Pyro Gold reagents (PSQ 96MA; Biotage, Charlottesville, VA, USA). A methylation density cut-off point of 15% was considered significant.
Western blotting. Expression of Ac-STAT3 in the HOSEpiC and HO-8910 cell lines was analyzed by western blotting using commercially available antibodies from Santa Cruz Biotechnology. The cell lysates were subjected to sodium dodecyl sulfate (SDS)-PAGE and subsequently transferred to a PVDF membrane. Blots were visualized using Amersham western blot detection reagent (GE Healthcare).
Cell proliferation assay. The cells were seeded in 96-well plates (5x10 4 /well) and incubated with 5-Aza (0.5-1 µM) for three days. The culture medium was changed daily to maintain the desired concentration of drugs. The cell proliferation assay was performed using the CyQuant ® NF Cell Assay kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Cell viability was measured at a wavelength of 490 nm.
Chromatin immunoprecipitation. ChIP assays were performed as previously described (17) with minor modifications. Briefly, chromatin samples isolated from HO-8910 cells and the STAT3 mutant were sonicated to shear the DNA to an average length of 200-500 bp. Samples were centrifuged and resuspended in dilution buffer, then incubated overnight, at 4˚C with primary antibody against STAT3 or DNMT1 (3 mg/ml). Protein agarose beads were added to isolate the immune complexes. After being washed from the agarose beads, the DNA-protein crosslinks in the immunopreciptated chromatin complexes were reversed by heating at 65˚C overnight, and the DNA was eluted. The ARHI DNA in the immunoprecipitates was then detected by PCR using gene-specific primers. Similarly, input was prepared by treating aliquots of chromatin with proteinase K, heated at 65˚C for 6 h for decrosslinking and the resulting DNA was subjected to RT-PCR for amplification. The primers for ARHI amplification were described above. The PCR products were analyzed by electrophoresis on 2% agarose gels. The signals were normalized as the amount of ARHI DNA in the immunoprecipitate/amount of DNA input.
Immunoprecipitation. Immunoprecipitation assays were performed as previously described (18) . Control HO-8910 cells and the mutant STAT3 cells (1x10 6 ) were incubated for 24 h and then treated with lysis buffer. For immunoprecipitation, 3 mg of anti-Stat3 or anti-NMT1 antibody was added to 2 mg of protein lysate. After overnight incubation at 4˚C, protein-G beads were added and incubated for 1.5 h at 4˚C. After washing with wash buffer, the immunoprecipitated proteins were eluted for western blotting.
Statistical analysis. Data are expressed as means ± SD. All statistical analyses were carried out using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Statistical comparisons were performed by one-way analysis of variance followed by the Student-Newman-Keuls test. P<0.05 was considered to indicate a statistically significant result.
Results

ARHI expression is downregulated in ovarian cancer cells.
ARHI has been identified as a tumor-suppressor gene and is of significant importance in modulating cell growth and apoptosis (19) . Consistent with previously conducted epidemiological studies, we found that ARHI expression was strikingly decreased in the majority of ovarian cancer tissues with loss of cell cycle control. Obvious staining for ARHI was present in epithelial cells in normal ovarian tissue sections (Fig. 1A) while almost no detectable expression in cancerous tissues was noted by immunohistochemical staining (Fig. 1B) , which was confirmed by RT-PCR measurement. Likewise, the ARHI mRNA level was determined in two normal and ovarian cancer epithelial cell lines, since EOC is clearly responsibility for 90% of ovarian neoplasias. Similar to the expression observed in the tissue sections, ARHI mRNA levels present were significantly decreased in the SKOV3 and HO-8910 cells, with less mRNA detected in the HO-8910 cells (Fig. 2) . Promoter methylation is associated with ARHI expression and tumor growth. It has been reported that promoter methylation plays vital roles in the inactivation of the ARHI gene; thus, we examined the methylation status of ARHI. As reported by Luo et al (8) , two CpG islands Ⅰ and Ⅱ were located within the ARHI promoter and adjacent exon 1. As shown in Fig. 3A , the proportions of methylated CpG island Ⅰ in NOE095 and HOSEpiC cells were 22.8±4.2% and 21.5±3.1%, respectively, whereas they were 58.7±5.4% and 80.6±10.2% in the SKOV3 and HO-8910 cells (P<0.05), suggesting that CpG island Ⅰ in the cancer cells was partially methylated or hypermethylated. Similarly, the density of CpG island Ⅱ methylation was increased in EOC cells compared with normal cells. Additionally, the predominate change in CpG island Ⅰ methylation density may shed light on its critical function in regulating ARHI expression. Therefore, RT-RCR was performed to determine the ARHI transcriptional level in each cell line in response to different methylation states, suggesting that the hypermethylated promoter inhibited transcription of ARHI (Fig. 3B) . Subsequently, we measured the effect of 5-Aza (5-aza-2'-deoxycytidine) on the viability of SKOV3 and HO-8910 cells using a cell proliferation assay and demonstrated that promoter methylation-mediated inactivation of the tumor-suppressor gene ARHI accounted for the cellular malignances, while 5-Aza-induced demethylation greatly diminished the proliferation of the cancer cells (Fig. 3C) .
Elevated STAT3 acetylation results in methylation of the ARHI gene promoter.
It has been proposed that STAT3 exerts an influence on CpG methylation, whereas the underlying mechanisms remain elusive. The present study was carried out to investigate the possible role of acetylated STAT3 in the methylation of CpG islands. The ARHI gene promoter in the HO-8910 cell line exhibited a higher methylation density than that in the SKOV3 cells; therefore, it was selected for the following studies. Correspondingly, the HO-8910 cell line harboring an endogenous STAT3 mutation with K685 converted to R685 was generated via a homologous recombination-mediated site-directed mutagenesis strategy as previously described (15) . First, we assessed the acetylation status of STAT3 by western blot analysis using an Ac-STAT3 (Fig. 4) . Meanwhile, Ac-STAT3 expression decreased sharply after treatment with resveratrol, a histone deacetylase (HDAC) activator or mutation of STAT3 K685R in HO-8910 cells.
Furthermore, we determined whether CpG I island methylation was associated with acetylated STAT3 in HO-8910 cells. As shown in Fig. 5 , ARHI promoter methylation was reduced in response to either resveratrol or K685 mutation-mediated decreased Ac-STAT3 (P<0.05). However, CpG I island methylation was increased by treatment with trichostatin, a histone deacetylase inhibitor that restrains the deacetylation of STAT3. Thus, STAT3 acetylation accelerated the methylation of the ARHI promoter, which regulated the expression of the tumor-suppressor gene ARHI.
STAT3 acetylation mediates STAT3-DNMT1 interaction
and recruitment to the gene promoter. It has been reported that binding of inducible transcription factors to DNA helps to recruit chromatin-modification machinery; therefore, chromatin immunoprecipitation was performed to determine whether DNMT1 was attached to ARHI promoter regions in the HO-8910 cell line and the corresponding variant STAT3 K685R cell line. Additionally, tumor-conditioned medium prepared from U251 human glioma cells was applied for the cultivation of HO-8910 and the variant cells to activate STAT3 and facilitate binding to the gene promoter. Furthermore, the binding of DNMT1 to ARHI was also subjected to ChIP assay. As illustrated in Fig. 6A , both STAT3 and DNM1 bound to the ARHI promoter in HO-8910 cells while this binding was reduced in the STAT3 K685 mutant, suggesting that acetylation of STAT3 regulated the attachment of STAT3 to the promoter. Notably, the decreased Ac-STAT3 in the mutant HO-8910 cells prevented the recruitment of DNMT1 to the ARHI gene. We then analyzed the Ac-STAT3-DNMT1 interaction using immunoprecipitation using anti-Ac-STAT3 antibody. Ac-STAT3 was found to interact with DNMT1 (Fig. 6B) , which is directly responsible for the modification of the DNA.
Discussion
ARHI is a maternally imprinted tumor-suppressor gene that is expressed in normal ovarian epithelium and is downregulated in the majority of ovarian cancers. Accumulating evidence has shown that decreased ARHI expression, either eliminated by LOH or post-transcriptional modulation, is implicated in tumor proliferation and development (20) . Our study was carried out to investigate whether methylation of the ARHI promoter gene could mute its expression and the underlying mechanism of ARHI methylation.
The present study also revealed that ARHI was downregulated in EOC as measured by IHC. To the best of our knowledge, ARHI possesses three CpG islands that are prone to methylation. CpG Ⅰ and Ⅱ are located within promoter regions, which encouraged us to consider the potential role of promoter methylation in the regulation of ARHI expression. In comparison with normal ovarian epithelium cells, the ARHI promoter was partially or heavily methylated in cancer cells in concert with reduced ARHI expression. Additionally, we demonstrated that CpG I hypermethylation suppressed ARHI promoter activity and regulated ARHI expression in ovarian cancer cells, which is similar to the outcomes obtained in breast cancer cells.
DNA methylation acts in a switch-like manner and is strongly correlated with the absence of gene expression and low levels of additional activating epigenetic markers (21) . Although the well-established role of DNA methylation in gene silencing has been extensively investigated, the precise mechanism of how the promoter methylation status is modified remains elusive. It has been reported that binding of inducible transcription factors to DNA helps recruit chromatin-modification machinery, which is responsible for the modification and expression of DNA (22) . Furthermore, STAT3 has been shown to increase CpG island methylation when acetylated (23) . Therefore, we explored whether STAT3 was associated with the methylation-induced ARHI silencing. It was confirmed that acetylated STAT3 bound to the ARHI promoter regions and recruited DNMT1 to suppress ARHI expression. Simultaneously, we found that specific inhibition of STAT3 acetylation using resveratrol reversed the suppression of ARHI and restrained cancer cell growth.
Taken together, our study demonstrated that the tumorsuppressor ARHI is downregulated in ovarian epithelium cancer cells and this downregulation can be partially ascribed 
B
A to the hypermethylation of CpG Ⅰ islands. Acetylated STAT3 bound and recruited DNMT1 to ARHI promoter regions. The activation of histone deacetylase or inhibition of acetyltransferase may hold promise for eliminating methylation-induced tumor-suppressor silencing, and further prospective studies are warranted to further clarify the modification machinery of Ac-STAT.
